Senate passes key FDA funding bill

Senate passes key FDA funding bill
© Greg Nash

Senators voted overwhelmingly Thursday to pass a key Food and Drug Administration (FDA) funding bill, sending it to President Trump's desk.

The Senate passed a five-year reauthorization of the FDA’s user fees in a 94-1 vote, with Sen. Bernie SandersBernie SandersChamber of Commerce argues against Democratic proposals for financial transaction taxes Top Sanders adviser: 'He is a little bit angry' Working Families Party endorses Warren after backing Sanders in 2016 MORE (I-Vt.) voting against the measure.

The bipartisan legislation was spearheaded by Sens. Lamar AlexanderAndrew (Lamar) Lamar Alexander The 13 Republicans needed to pass gun-control legislation Liberal group urges Senate panel to vote against Scalia as Labor secretary Suburban anxiety drives GOP on guns MORE (R-Tenn.) and Patty MurrayPatricia (Patty) Lynn MurrayOvernight Health Care: Juul's lobbying efforts fall short as Trump moves to ban flavored e-cigarettes | Facebook removes fact check from anti-abortion video after criticism | Poll: Most Democrats want presidential candidate who would build on ObamaCare Trump's sinking polls embolden Democrats to play hardball Democrats threaten to withhold defense votes over wall MORE (D-Wash.), the top lawmakers on the Senate Health Committee, and represents a major contrast from the partisan rancor surrounding the Senate's recent efforts to repeal ObamaCare.

ADVERTISEMENT

The bill passed Thursday renews the FDA’s authority to collect fees from the prescription drug and medical device industries, which will account for $8-9 billion over 5 years and is over a quarter of all FDA funding.

The fees help speed up the approval of new drug and devices. The funding reauthorizations are based on recommendations from industry groups and the FDA after a public process, and come about a month before the current user fee agreement is set to expire.

The White House hasn’t said if it will sign the user fee bill. In a statement of administrative policy issued in July after the bill passed the House, the White House expressed concern with some minor provisions, though it did not threaten a veto.

The White House has also urged support for Trump’s budget, which asks industry to finance 100 percent of FDA's premarket review.

“In an era of renewed fiscal restraint, industries that benefit directly from FDA's work should pay for it,” the White House said.

The legislation passed after lawmakers reached a deal with Sen. Ron JohnsonRonald (Ron) Harold JohnsonDemocratic senator warns O'Rourke AR-15 pledge could haunt party for years Conservatives offer stark warning to Trump, GOP on background checks Hillicon Valley: Google to promote original reporting | Senators demand answers from Amazon on worker treatment | Lawmakers weigh response to ransomware attacks MORE (R-Wis.) to hold a separate vote on his “right to try” legislation, which would give terminally ill patients access to experimental drugs that haven’t yet received FDA approval. Johnson’s bill passed by unanimous consent Thursday.